Research progress of immune checkpoint agonist for solid tumor treatments

VernacularTitle:免疫检查点激动剂治疗实体瘤的研究进展
Author: Hongyun YUE ¹ ; Baihong ZHANG
Author Information

1. 中国人民解放军联勤保障部队第九四〇医院眼科，兰州　730050
Keywords: Neoplasms; Stimulatory checkpoint molecules; Immune agonist antibody; Therapy
From: Journal of International Oncology 2023;50(5):290-293
CountryChina
Language:Chinese
Abstract: Immune checkpoint consists of inhibitory and stimulatory molecules. Drugs blocking inhibitory checkpoint programmed cell death receptor-1 (PD-1) and cytotoxic T lymphocyte-associated molecule-4 (CTLA-4) are currently utilized for wide variety of human cancers. Agonists of stimulatory checkpoints such as GITR, OX40, 4-1BB, ICOS, CD40 and STING are undergoing critical clinical trials. Immune checkpoint agonists that affect stimulatory checkpoint molecules develop rapidly, and immune agonist antibodies thus represent an important approach for solid tumor treatments.